Moreover, specific mutations in inositide regulating enzymes including PLCγ2, AKT3 and PIK3CD were associated with Azacytidine and Lenalidomide therapy failure in MDS leading to a higher risk of AML progression (43). Here, PIK3CD is linked to acute myeloid leukemia.